120 related articles for article (PubMed ID: 24937026)
21. Effect and safety of 17 beta-estradiol vaginal tablet in postmenopausal women with urogenital symptoms.
Manonai J; Theppisai U; Chittacharoen A
J Med Assoc Thai; 2001 Jul; 84(7):1015-20. PubMed ID: 11759960
[TBL] [Abstract][Full Text] [Related]
22. Promestriene, a specific topic estrogen. Review of 40 years of vaginal atrophy treatment: is it safe even in cancer patients?
Del Pup L; Di Francia R; Cavaliere C; Facchini G; Giorda G; De Paoli P; Berretta M
Anticancer Drugs; 2013 Nov; 24(10):989-98. PubMed ID: 24080714
[TBL] [Abstract][Full Text] [Related]
23. Alternatives to oral estrogen replacement. Transdermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of delivery.
Baker VL
Obstet Gynecol Clin North Am; 1994 Jun; 21(2):271-97. PubMed ID: 7936545
[TBL] [Abstract][Full Text] [Related]
24. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms.
Al-Azzawi F; Buckler HM;
Climacteric; 2003 Jun; 6(2):118-27. PubMed ID: 12841882
[TBL] [Abstract][Full Text] [Related]
25. [Topical hormonal treatment and urogenital atrophy].
Sitruk-Ware R; Thomas JL
Praxis (Bern 1994); 1997 Aug; 86(33):1245-8. PubMed ID: 9381009
[TBL] [Abstract][Full Text] [Related]
26. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
Tan O; Bradshaw K; Carr BR
Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
[TBL] [Abstract][Full Text] [Related]
27. Current overview of the management of urogenital atrophy in women with breast cancer.
Pruthi S; Simon JA; Early AP
Breast J; 2011; 17(4):403-8. PubMed ID: 21645165
[TBL] [Abstract][Full Text] [Related]
28. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
[TBL] [Abstract][Full Text] [Related]
29. An open-label randomized trial to determine the most effective regimen of vaginal estrogen to reduce the prevalence of atrophic changes reported in postmenopausal cervical smears.
Bateson DJ; Weisberg E
Menopause; 2009; 16(4):765-9. PubMed ID: 19407678
[TBL] [Abstract][Full Text] [Related]
30. Vaginal rings for menopausal symptom relief.
Ballagh SA
Drugs Aging; 2004; 21(12):757-66. PubMed ID: 15382956
[TBL] [Abstract][Full Text] [Related]
31. Oestradiol-releasing vaginal ring for treatment of postmenopausal urogenital atrophy.
Smith P; Heimer G; Lindskog M; Ulmsten U
Maturitas; 1993 Mar; 16(2):145-54. PubMed ID: 8483427
[TBL] [Abstract][Full Text] [Related]
32. [Continuous, low dosage estradiol administration with a vaginal ring: a placebo-controlled study].
Casper F; Petri E; Benninghoff B
Zentralbl Gynakol; 1998; 120(9):449-53. PubMed ID: 9796090
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial.
Bachmann G; Lobo RA; Gut R; Nachtigall L; Notelovitz M
Obstet Gynecol; 2008 Jan; 111(1):67-76. PubMed ID: 18165394
[TBL] [Abstract][Full Text] [Related]
34. Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
López-Belmonte J; Nieto C; Estevez J; Delgado JL; del Prado JM
Maturitas; 2012 Aug; 72(4):353-8. PubMed ID: 22683083
[TBL] [Abstract][Full Text] [Related]
35. The estradiol vaginal ring--a study of existing clinical data.
Bachmann G
Maturitas; 1995 Dec; 22 Suppl():S21-9. PubMed ID: 8775773
[TBL] [Abstract][Full Text] [Related]
36. Effects of Glycine max (L.) Merr. soy isoflavone vaginal gel on epithelium morphology and estrogen receptor expression in postmenopausal women: a 12-week, randomized, double-blind, placebo-controlled trial.
Lima SM; Bernardo BF; Yamada SS; Reis BF; da Silva GM; Galvão MA
Maturitas; 2014 Jul; 78(3):205-11. PubMed ID: 24856055
[TBL] [Abstract][Full Text] [Related]
37. Vaginal ring an HT alternative.
Cothran MM; Engberg S
Nurse Pract; 2004 Jul; 29(7):54-5. PubMed ID: 15238860
[No Abstract] [Full Text] [Related]
38. A multicentre Australian trial of low dose estradiol therapy for symptoms of vaginal atrophy using a vaginal ring as delivery system.
Fraser IS; Ayton R; Farrell E; Weisberg E; Darling G; Murkies A
Maturitas; 1995 Dec; 22 Suppl():S41. PubMed ID: 8775776
[No Abstract] [Full Text] [Related]
39. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet.
Simon J; Nachtigall L; Gut R; Lang E; Archer DF; Utian W
Obstet Gynecol; 2008 Nov; 112(5):1053-60. PubMed ID: 18978105
[TBL] [Abstract][Full Text] [Related]
40. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group.
Casper F; Petri E
Int Urogynecol J Pelvic Floor Dysfunct; 1999; 10(3):171-6. PubMed ID: 10430010
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
